Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Tiemann

P1.01-82 Risk of Not Receiving 2nd Line Therapy Is High in EGFR Mt+ Pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR Mt+ PTS

Journal of Thoracic Oncology

English

Related publications

P1.15-19 Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real World Data

Journal of Thoracic Oncology

English

OA07.03 Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC PTS With Oligometastatic or Oligoprogressive Liver Metastases

Journal of Thoracic Oncology

English

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

Oncotarget

Oncology

2017

English

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

Journal of Thoracic Oncology

English

P1.01-111 EGFR Exon20 Insertion Patients Treated With First-Line Chemotherapy in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients With Advanced NSCLC Receiving EGFR-TKIs

Journal of Thoracic Oncology

English

First-Line Treatment of EGFR-mutated Nonsmall Cell Lung Cancer: Critical Review on Study Methodology

European Respiratory Review

Pulmonary

Respiratory Medicine

2014

English

P1.01-01 ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Tiemann

P1.01-82 Risk of Not Receiving 2nd Line Therapy Is High in EGFR Mt+ Pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR Mt+ PTS

Related publications

P1.15-19 Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real World Data

OA07.03 Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC PTS With Oligometastatic or Oligoprogressive Liver Metastases

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

P1.01-111 EGFR Exon20 Insertion Patients Treated With First-Line Chemotherapy in Non-Small Cell Lung Cancer

MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients With Advanced NSCLC Receiving EGFR-TKIs

First-Line Treatment of EGFR-mutated Nonsmall Cell Lung Cancer: Critical Review on Study Methodology

P1.01-01 ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea